Articles

Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy. 

Although maspin is believed to reduce the formation, development, and spread of tumors in several aggressive cancers (breast, ovarian, and head and neck cancers), it has been challenging to utilize this information and predict how cancer patients will fare with its use; the presence of maspin has been associated with both good and bad prognoses. The cause of this irregularity was considered to be based on the location of maspin within the cell, whether in the nucleus or in the cytoplasm, according to Drs. Read More ›

In young women with early-stage breast cancer, coupling the GnRH analogue triptorelin with chemotherapy led to a 17% reduction in the occurrence of early menopause, according to a report in the July 20 issue of JAMA.

The phase III study results showed:

With 2 treatment regimens for advanced Hodgkin lymphoma equivalent in their long-term effectiveness, one regimen’s less severe side-effect profile may play a role in treatment choice, according to study results from the Gruppo Italiano di Terapie Innovative nei Linfomi and the Intergruppo Italiano Linfomi.

Maintaining a healthy body weight is important for all patients. But, this is especially true for women with a breast cancer diagnosis, as an analysis of the California Teachers Study has shown a correlation between breast cancer deaths and body mass index (BMI).

Patients with HER2+ breast cancer who develop resistance to trastuzumab may soon have an alternative therapy, according to recent findings published in Clinical Cancer Research.

Short-term androgen-deprivation therapy (ADT) for 4 months before and during radiotherapy increases overall survival rates and decreases disease-specific mortality rates in men with intermediate-risk prostate cancer, according to an interventional phase 3 study.

Continuous use of aspirin for 5 years or more reduces the risk of cutaneous melanoma by almost half, according to results of a case-control study. Continuous use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) also reduces risk, but only by 25%.

Patients diagnosed with high-grade non–muscle-invasive bladder cancer are not receiving guideline-recommended care, according to an analysis of data from the SEER-Medicare Linked Database.